Standpoint Research Cuts Pfizer (PFE) to Hold Following Q3 Report
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $24.29 +2.62%
Rating Summary:
15 Buy, 19 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
15 Buy, 19 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Standpoint Research downgraded shares of Pfizer (NYSE: PFE) from Buy to Hold.
Shares of Pfizer are up about 2.4 percent Tuesday morning following better-than-expected Q3 results and raised FY11 guidance this morning.
For more ratings news on Pfizer click here and for the rating history of Pfizer click here.
Shares of Pfizer are up about 2.4 percent Tuesday morning following better-than-expected Q3 results and raised FY11 guidance this morning.
For more ratings news on Pfizer click here and for the rating history of Pfizer click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'
- Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
Create E-mail Alert Related Categories
DowngradesRelated Entities
Standpoint Research, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
